A Study to Evaluate the Safety and Immunogenicity of the mRNA COVID-19 Vaccines in Healthy Children Between 6 Months to Less Than 6 Years of Age
An Open-Label, Phase 3 Study to Evaluate the Safety and Immunogenicity of mRNA Vaccines for SARS-CoV-2 Variants in Participants Aged 6 Months to < 6 Years
Sponsor: ModernaTX, Inc.
This PHASE3 trial investigates SARS-CoV-2 and is currently completed. ModernaTX, Inc. leads this study, which shows 18 recorded versions since 2022 — indicating substantial longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.
Status Flow
Change History
18 versions recorded-
Dec 2025 — Present [monthly]
Completed PHASE3
Status: Recruiting → Completed
-
Sep 2025 — Dec 2025 [monthly]
Recruiting PHASE3
-
Apr 2025 — Sep 2025 [monthly]
Recruiting PHASE3
-
Dec 2024 — Apr 2025 [monthly]
Recruiting PHASE3
-
Nov 2024 — Dec 2024 [monthly]
Recruiting PHASE3
▶ Show 13 earlier versions
-
Oct 2024 — Nov 2024 [monthly]
Recruiting PHASE3
-
Sep 2024 — Oct 2024 [monthly]
Recruiting PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE3
-
Jun 2024 — Jul 2024 [monthly]
Recruiting PHASE3
-
May 2024 — Jun 2024 [monthly]
Recruiting PHASE3
Status: Active Not Recruiting → Recruiting
-
Apr 2024 — May 2024 [monthly]
Active Not Recruiting PHASE3
-
Jun 2023 — Apr 2024 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
May 2023 — Jun 2023 [monthly]
Recruiting PHASE3
-
Apr 2023 — May 2023 [monthly]
Recruiting PHASE3
-
Mar 2023 — Apr 2023 [monthly]
Recruiting PHASE3
-
Nov 2022 — Mar 2023 [monthly]
Recruiting PHASE3
-
Sep 2022 — Nov 2022 [monthly]
Recruiting PHASE3
-
Jul 2022 — Sep 2022 [monthly]
Recruiting PHASE3
First recorded
Jun 2022
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- ModernaTX, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .